Buparlisib, is already being studied (phase IB) in association with lapatinib, a dual tyrosine kinase inhibitor which abrogates the HER-2/neu and EGFR pathways, in HER-2 positive advanced breast cancer that is resistant to trastuzumab, since the PI3K cascade is involved in trastuzumab resistance, and early conclusions demonstrate that this association is feasible for this kind of breast cancer [123]. This evidence concerns the gene EGFR and breast cancer.